The stock has a 36-month beta value of 1.90. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MBIO is 31.32M, and at present, short sellers hold a 9.44% of that float. On July 22, 2024, the average trading volume of MBIO was 29.72M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MBIO) stock’s latest price update
The stock price of Mustang Bio Inc (NASDAQ: MBIO) has plunged by -7.73 when compared to previous closing price of 0.32, but the company has seen a -25.23% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-06-28 that NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) — Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s management commentary, recent developments, outlook, and risks.
MBIO’s Market Performance
Mustang Bio Inc (MBIO) has experienced a -25.23% fall in stock performance for the past week, with a -47.17% drop in the past month, and a -13.32% drop in the past quarter. The volatility ratio for the week is 10.92%, and the volatility levels for the past 30 days are at 17.98% for MBIO. The simple moving average for the last 20 days is -34.39% for MBIO stock, with a simple moving average of -71.18% for the last 200 days.
Analysts’ Opinion of MBIO
Many brokerage firms have already submitted their reports for MBIO stocks, with BTIG Research repeating the rating for MBIO by listing it as a “Buy.” The predicted price for MBIO in the upcoming period, according to BTIG Research is $11 based on the research report published on May 18, 2021 of the previous year 2021.
B. Riley FBR, on the other hand, stated in their research note that they expect to see MBIO reach a price target of $9. The rating they have provided for MBIO stocks is “Buy” according to the report published on October 02nd, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to MBIO, setting the target price at $7 in the report published on November 20th of the previous year.
MBIO Trading at -13.48% from the 50-Day Moving Average
After a stumble in the market that brought MBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.59% of loss for the given period.
Volatility was left at 17.98%, however, over the last 30 days, the volatility rate increased by 10.92%, as shares sank -46.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.53% upper at present.
During the last 5 trading sessions, MBIO fell by -25.20%, which changed the moving average for the period of 200-days by -84.81% in comparison to the 20-day moving average, which settled at $0.4384. In addition, Mustang Bio Inc saw -78.07% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MBIO
Current profitability levels for the company are sitting at:
- -13.28 for the present operating margin
- -0.08 for the gross margin
The net margin for Mustang Bio Inc stands at -13.91. The total capital return value is set at 13.45. Equity return is now at value -322.45, with -90.93 for asset returns.
Based on Mustang Bio Inc (MBIO), the company’s capital structure generated -0.94 points at debt to capital in total, while cash flow to debt ratio is standing at -15.43. The debt to equity ratio resting at -0.48. The interest coverage ratio of the stock is -296.78.
Currently, EBITDA for the company is -48.5 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 3.93. The receivables turnover for the company is 0.43for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.53.
Conclusion
To sum up, Mustang Bio Inc (MBIO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
